Abstract：Objective To investigate the clinical effect of Desferridone combined with Desferrimide in the treatment of children with severe thalassemia. Methods The clinical data of 50 children with severe thalassemia admitted to our hospital from February 2017 to January 2018 were analyzed retrospectively. According to different treatment methods,they were divided into observation group (25 cases) and control group (25 cases). The children in the observation group were treated with Desferridone and Deferoxamine, while the children in the control group were treated with Deferoxamine. The total effective rate, adverse reactions, serum ferritin (SF) and urinary iron excretion were compared between the two groups. Results The total effective rate of the observation group was higher than that of the control group, and the difference was statistically significant (P＜0.05). There was no significant difference in SF concentration and urinary iron excretion before treatment between the two groups (P＞0.05). After treatment, the SF concentration in the observation group was lower than that in the control group, and the urinary iron excretion was higher than that in the control group, and the differences were statistically significant (P＜0.05). There was no significant difference in the total incidence of adverse reactions between the two groups (P＞0.05). Conclusion The effect of desferridone combined with deferoxamine in the treatment of severe thalassemia is exact, which can reduce the iron load of children and has good safety. It is worthy of popularization and application.
罗玉婷; 陈捷; 梁达开; 戴本启. 去铁酮联合去铁胺治疗重症地中海贫血患儿的临床效果[J]. 中国当代医药, 2020, 27(7): 142-144.
LUO Yu-ting; CHEN Jie; LIANG Da-kai; DAI Ben-qi. Clinical effect of Desferridone combined with Desferrimide in the treatment of children with severe thalassemia. 中国当代医药, 2020, 27(7): 142-144.
京公网安备 11010502046607号